Richard Kovach, MD
Cardiovascular Disease · Browns Mills, NJNPI 1144209891
Payments from drug & device makers
Across 635 payments — averaging $726.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$147K
- Boston Scientific$139K
- Abbott$52K
- Shockwave Medical, Inc$52K
- Philips North America LLC$24K
- Siemens Medical Solutions USA, Inc.$12K
- plus $35K from 31 others
Across 3 payments — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$900
What the payments were for
- Consulting fees$49,56517%
- Speaking & faculty fees$57,70019%
- Travel & lodging$22,8388%
- Food & beverage$24,3438%
- Other$145,93649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 5 | $146,772 |
| Boston Scientific | 156 | $139,385 |
| Abbott | 105 | $51,977 |
| Shockwave Medical, Inc | 74 | $51,528 |
| Philips North America LLC | 35 | $24,451 |
| Siemens Medical Solutions USA, Inc. | 22 | $11,988 |
| Medtronic(2 entities) | 34 | $8,057 |
| Venturemed Group, Inc. | 11 | $7,636 |
| Edwards Lifesciences | 26 | $3,858 |
| Abiomed | 61 | $3,006 |
| Cardiovascular Systems Inc. | 20 | $2,347 |
| Ancora Heart, Inc. | 10 | $1,964 |
| Endologix LLC | 4 | $1,881 |
| Penumbra, Inc. | 10 | $860 |
| Saranas, Inc. | 10 | $657 |
| Cordis Corporation | 2 | $600 |
| Intact Vascular, Inc. | 2 | $600 |
| Terumo Medical Corporation | 1 | $450 |
| Inari Medical, Inc. | 6 | $426 |
| Verge Medical, Inc. | 7 | $380 |
| Angiodynamics, Inc. | 5 | $328 |
| Cardiac Dimensions, Inc. | 4 | $291 |
| Johnson & Johnson | 3 | $246 |
| Biotronik Inc. | 4 | $220 |
| Trireme Medical LLC | 1 | $200 |
| W. L. Gore & Associates, Inc. | 2 | $193 |
| Cagent Vascular Inc | 2 | $172 |
| Surmodics, Inc. | 1 | $136 |
| Teleflex LLC | 3 | $123 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| AstraZeneca | 1 | $96 |
| Boehringer Ingelheim | 1 | $79 |
| Cvrx, Inc. | 2 | $68 |
| Nipro Medical Corporation | 1 | $40 |
| Cardinal Health 200 LLC | 1 | $33 |
| Avinger Inc. | 1 | $25 |
| Veryan Medical Incorporated | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$50,743
- US Und$15,000
- Omnilink Elite vascular stent system$6,400
- FLEX Scoring Catheter$5,797
- GENERAL - THERAPIES$4,396
- GENERAL VASCULAR ACCESS$4,339
- Spectranetics Undiv$4,000
- GENERAL - STRUCTURAL HEART$4,000
- HawkOne$3,000
- (9520) IGT Devices Undivided$2,658
- CoreValve Evolut$2,621
- Diamondback Peripheral$1,966
- Diamondback Coronary$1,966
- AccuCinch$1,860
- Impella$1,806
- Xience V coronary stent system$1,733
- Torus Stent Graft System$1,650
- ENDOCROSS Device$1,650
- FLEX Vessel Prep System$1,600
- PASCAL$1,554
How this compares
$461,198 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 14 | $8,454 |
| EliquisApixaban | 13 | $7,840 |
| ClopidogrelClopidogrel Bisulfate | 17 | $326 |
| Atorvastatin Calcium | 13 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $96 | $8,45414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Browns Mills
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.